Depression treatment for Deerfield Beach — measurement-based, 22 minutes away.

RECO Health treats major depressive disorder at PHP and IOP levels 22 minutes north of Deerfield Beach — a 13-mile drive up A1A from The Cove or Hillsboro Beach. Every treatment plan is anchored to a PHQ-9 trajectory and adjusted by measurement, not clinical impression. When two adequate antidepressant trials fail, escalation to rTMS, IV ketamine, or esketamine happens on schedule rather than after months of drift — and every interventional treatment is delivered on-site by RECO's psychiatry team.

Deerfield Beach sits 13 miles south of RECO Health’s Delray Beach campus — a 22-minute drive up A1A that many clients from The Cove, Pioneer Park, and Hillsboro Beach describe as the smallest useful buffer between the environment tied to a depressive episode and the treatment setting itself. That buffer matters as much for depression as it does for substance use: enough separation to interrupt the routines that reinforce inertia and withdrawal, close enough that family, custody schedules, and part-time work do not have to pause. RECO offers depression treatment at Partial Hospitalization and Intensive Outpatient levels with in-house psychiatry, measurement-based dosing, and interventional escalation when standard treatment stalls.

Diagnostic formulation and severity staging

Every intake at RECO Health begins with a full DSM-5-TR diagnostic interview rather than a symptom checklist. The evaluating psychiatrist distinguishes major depressive disorder from persistent depressive disorder (dysthymia), bipolar II depression, adjustment disorder with depressed mood, and depression secondary to hypothyroidism, B12 deficiency, or active alcohol or benzodiazepine use. Missing a bipolar diathesis and prescribing an unopposed SSRI is one of the most common preventable errors in outpatient psychiatry; RECO screens with the MDQ and takes a detailed family history before committing to an antidepressant.

Severity is anchored to the PHQ-9 at admission and remeasured weekly. C-SSRS captures suicidal ideation, intent, plan, and behavior at every clinical contact — not only at intake. Baseline labs include TSH, free T4, B12, folate, vitamin D, CBC, and a metabolic panel; women of reproductive age receive a pregnancy test before esketamine or ketamine is considered. GAD-7 is added when anxiety symptoms are prominent, and ASRS when adult ADHD is a plausible driver of anhedonia and executive collapse.

Level of care follows severity. PHP — six hours a day, five days a week — is indicated for PHQ-9 scores above 20, active suicidal ideation with intent, or functional collapse that prevents self-care. IOP — three hours a day, three to five days a week — fits moderate depression where the client can maintain safety and basic function between sessions. Step-down between levels is a clinical decision anchored to PHQ-9 trajectory and functional recovery, not a calendar decision.

Pharmacology sequenced by evidence, not habit

First-line pharmacotherapy for major depressive disorder is an SSRI (sertraline, escitalopram) or SNRI (venlafaxine, duloxetine), titrated to a therapeutic dose and held there for a full four to six week response window. Subtherapeutic dosing followed by premature switching is one of the most common reasons clients arrive at RECO already labeled “treatment-resistant” when they have not yet completed an adequate trial of anything.

Partial responders — PHQ-9 falling but not below 10 by week six — are augmented before they are switched. Aripiprazole (2-5 mg) has the strongest FDA-supported augmentation evidence; lithium at a target level of 0.6-0.8 mEq/L remains a rigorously validated option; bupropion adds noradrenergic and dopaminergic activation for anergic, anhedonic presentations. Quetiapine XR is used selectively where sleep architecture is destroyed. Buspirone is available as an SSRI augmentation for anxious depression. Non-responders — no meaningful PHQ-9 movement at therapeutic dose — are switched across mechanism class.

Treatment-resistant depression is defined operationally as two adequate antidepressant trials at adequate dose and duration without remission. At that threshold RECO stops cycling antidepressants and stages the client for interventional treatment. Every medication decision — start, dose, augmentation, switch, discontinuation — is documented against a PHQ-9 trajectory so the next clinician can see what was tried, at what dose, for how long, and why it changed.

Behavioral therapy modalities with evidence for depression

Antidepressant medication alone reaches remission in roughly a third of depressed outpatients. RECO’s therapy protocol is built around the three modalities with the strongest randomized evidence for unipolar depression: Cognitive Behavioral Therapy for depression, Behavioral Activation, and Interpersonal Therapy. CBT targets the cognitive distortions — catastrophizing, all-or-nothing thinking, personalization — that maintain low mood, and the behavioral withdrawal that starves the client of reinforcement. Behavioral Activation reverses that withdrawal directly by scheduling rewarding, mastery-generating, and social activities before the client feels ready. IPT addresses grief, role transition, and unresolved interpersonal conflict as depression drivers.

Therapists run these modalities to protocol — session-by-session structure, between-session assignments, and outcome tracking — rather than as a loose collection of techniques. For clients with trauma-linked depression, Cognitive Processing Therapy or EMDR is layered in once affect regulation is stable enough to tolerate reprocessing. For clients whose depression sits inside an alcohol or opioid use disorder, Motivational Interviewing runs alongside every therapy contact and CBT is adapted for co-occurring presentations rather than sequenced after “sobriety first.”

Group work supplements but does not replace individual therapy. Skills groups drawn from DBT — distress tolerance, emotion regulation, interpersonal effectiveness — are used for clients with affective instability or non-suicidal self-injury, and ACT-informed groups address values clarification and psychological flexibility. Neither replaces a formulation-driven individual treatment plan.

Escalation pathway when medication and therapy aren’t enough

Roughly a third of patients with major depression do not remit after two adequate antidepressant trials. RECO’s escalation pathway is written in advance so those clients do not spend six additional months drifting through a fifth SSRI.

Repetitive Transcranial Magnetic Stimulation is offered on the standard FDA-cleared 10 Hz protocol delivered to the left dorsolateral prefrontal cortex — 3000 pulses per session at 120% of motor threshold, five sessions per week for six weeks (30 sessions), followed by a six-session taper. Motor threshold mapping and coil positioning are re-verified at every session. rTMS is durable, non-sedating, and covered by most commercial payers once two failed antidepressant trials are documented.

IV ketamine (0.5 mg/kg over 40 minutes, six-infusion induction across two to three weeks) is used when suicidality or functional collapse does not allow the six-week wait for rTMS to work. Response typically emerges within hours to days; a maintenance schedule is negotiated based on durability at week four. Esketamine (Spravato) is the alternative where REMS-monitored intranasal delivery is preferred and where commercial insurance covers it under the FDA treatment-resistant depression indication. All interventional treatment is delivered on-site by RECO’s psychiatry team, not referred out.

What to expect on your first visit

The first appointment is a 90-minute psychiatric evaluation followed by a therapy intake and, where clinically indicated, same-day labs. The evaluating psychiatrist takes a full psychiatric history, medical history, complete medication history — including doses and durations of every prior antidepressant — family history, substance use history, and trauma history. The client leaves with a working DSM-5-TR diagnosis, a PHQ-9 baseline, a C-SSRS score, an initial medication plan or continuation plan, and a therapy schedule.

Clients are not asked to repeat their history to a different clinician the following week. Records from prior psychiatrists, therapists, and hospitals are requested at intake and reviewed before the second appointment. If the client is already on an SSRI at a subtherapeutic dose, the plan is usually to titrate rather than switch; if they are on a fourth antidepressant with no PHQ-9 movement, the plan is usually to stage rTMS or ketamine rather than start a fifth.

Insurance and admissions from Deerfield Beach

RECO Health is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS for PHP and IOP depression care. Interventional coverage varies: rTMS is commonly covered for treatment-resistant depression once two failed antidepressant trials are documented, and esketamine is covered under most commercial plans through the manufacturer’s REMS program. IV ketamine for depression is typically out-of-pocket and is priced transparently at intake.

Admissions from Deerfield Beach — Cresthaven, Goldcoast Centre, Pioneer Park, or the Hillsboro Beach corridor — are usually scheduled within 24 to 72 hours of the first call. Verification of benefits takes 15 to 30 minutes. The drive up A1A is 22 minutes; transport assistance is available for clients whose depressive symptoms make safe driving impractical during the acute phase of treatment.

Serving residents of: The Cove, Pioneer Park, Hillsboro Beach, Cresthaven, Goldcoast Centre.